Moderna (MRNA) Reports Q1 Revenues Below Estimates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Moderna (MRNA) Reports Publication of Phase 1 Data for mRNA Vaccines Against Two Potential Pandemic Influenza Strains
May 10, 2019 9:00 AM EDTModerna, Inc., (NASDAQ: MRNA) today announced the publication of results from two Phase 1 clinical studies showing that mRNA vaccines against H10N8 and H7N9 influenza viruses were well-tolerated and elicited robust immune responses. The results support the potential of mRNA-based vaccines to quickly and effectively address pandemic influenza strains.
Published in the scientific journal Vaccine, the findings include results from two randomized, placebo-controlled, double-blind Phase 1 studies. Both studies met their primary safety and secondary immunogenicity endpoints, and there were no vaccine-related serious adverse events (AEs) reported. In both studies,... More
